Final Results from a Phase 1 Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or with Ipilimumab for Advanced/Metastatic Genitourinary Tumours
Year: 2023
Type: preprint
Source: SSRN Electronic Journal
DOI: 10.2139/ssrn.4488071
Authors: Andrea Apolo, Daniel M. Girardi, Scot A. Niglio, Rosa Nadal, Andre R. Kydd, Nicholas Simon, Lisa Ley, Lisa M. Cordes, Elias Chandran, Seth M. Steinberg, Jane Trepel, Sunmin Lee, Min-Jung Lee, Shraddha Rastogi, Nahoko Sato, Liang Cao, A. Rouf Banday, Salah Boudjadi, Maria J. Merino, Antoun Toubaji, Dilara Akbulut, Bernadette Redd, Mohammad Hadi Bagheri, Rene Costello, Sandeep Gurram, Piyush K. Agarwal, Heather J. Chalfin, Vladimir Valera, Howard Streicher, John Joseph Wright, Elad Sharon, William D. Figg, Howard Parnes, James Gulley, Biren Saraiya, Sumanta K. Pal, David Quinn, Mark N. Stein, Primo N Lara, Donald P. Bottaro, Amir Mortazavi
Institutions: National Institutes of Health, Government of the United States of America, Center for Cancer Research, National Cancer Institute, University of Southern California, Harvard University, Rutgers, The State University of New Jersey, Rutgers Cancer Institute, City Of Hope National Medical Center, City of Hope, Herbert Irving Comprehensive Cancer Center, Columbia University, UC Davis Comprehensive Cancer Center, University of California, Davis, The Ohio State University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4382046548